274 related articles for article (PubMed ID: 16924646)
1. Treatment of anemia in myelodysplastic syndrome with darbepoetin and granulocyte colony stimulating factor.
Rose S; Ali Y; Maffei B; Saidi P
Am J Hematol; 2007 Mar; 82(3):245-6. PubMed ID: 16924646
[No Abstract] [Full Text] [Related]
2. Darbepoetin alfa for anemia with myelodysplastic syndrome.
Seastone DJ; Gerds AT
Expert Rev Hematol; 2015 Apr; 8(2):139-46. PubMed ID: 25579702
[TBL] [Abstract][Full Text] [Related]
3. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM.
Kelaidi C; Beyne-Rauzy O; Braun T; Sapena R; Cougoul P; Adès L; Pillard F; Lamberto C; Charniot JC; Guerci A; Choufi B; Stamatoullas A; Slama B; De Renzis B; Ame S; Damaj G; Boyer F; Chaury MP; Legros L; Cheze S; Testu A; Gyan E; Béné MC; Rose C; Dreyfus F; Fenaux P
Ann Hematol; 2013 May; 92(5):621-31. PubMed ID: 23358617
[TBL] [Abstract][Full Text] [Related]
4. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study.
Mannone L; Gardin C; Quarre MC; Bernard JF; Vassilieff D; Ades L; Park S; Vaultier S; Hamza F; Beyne-rauzy MO; Cheze S; Giraudier S; Agape P; Legros L; Voillat L; Dreyfus F; Fenaux P;
Br J Haematol; 2006 Jun; 133(5):513-9. PubMed ID: 16681638
[TBL] [Abstract][Full Text] [Related]
5. Treatment of anemia with erythroid stimulating agents in myelodysplastic syndromes.
Della Porta MG
Leuk Res; 2011 Jan; 35(1):22-3. PubMed ID: 20727588
[No Abstract] [Full Text] [Related]
6. Efficacy of granulocyte colony stimulating factor in combination with erythropoiesis stimulating agents for treatment of anemia in patients with lower risk myelodysplastic syndromes: A systematic review.
Affentranger L; Bohlius J; Hallal M; Bonadies N
Crit Rev Oncol Hematol; 2019 Apr; 136():37-47. PubMed ID: 30878127
[TBL] [Abstract][Full Text] [Related]
7. Dramatic hyperleukocytosis after treatment of myelodysplastic syndrome with pegfilgrastim and darbepoetin-alfa.
Heydrich BN; Schoch R; Horst HA; Kneba M
Ann Hematol; 2008 Jan; 87(1):77-8. PubMed ID: 17710399
[No Abstract] [Full Text] [Related]
8. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin.
Mantovani L; Lentini G; Hentschel B; Wickramanayake PD; Loeffler M; Diehl V; Tesch H
Br J Haematol; 2000 May; 109(2):367-75. PubMed ID: 10848827
[TBL] [Abstract][Full Text] [Related]
9. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes.
Giraldo P; Nomdedeu B; Loscertales J; Requena C; de Paz R; Tormo M; Navarro P; Benedit P; Gasquet JA;
Cancer; 2006 Dec; 107(12):2807-16. PubMed ID: 17115424
[TBL] [Abstract][Full Text] [Related]
10. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.
Mundle S; Lefebvre P; Vekeman F; Duh MS; Rastogi R; Moyo V
Cancer; 2009 Feb; 115(4):706-15. PubMed ID: 19152429
[TBL] [Abstract][Full Text] [Related]
11. Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond.
Kelaidi C; Fenaux P
Expert Opin Biol Ther; 2010 Apr; 10(4):605-14. PubMed ID: 20201708
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of a patient with myelodysplastic syndrome (RAEB) with Darbepoetin-alfa in combination with Pegfilgrastim.
Jakob A; Hirsch FW; Engelhardt M
Ann Hematol; 2005 Oct; 84(10):694-5. PubMed ID: 15931534
[No Abstract] [Full Text] [Related]
13. Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes.
Santini V
Oncologist; 2011; 16 Suppl 3():35-42. PubMed ID: 21930833
[TBL] [Abstract][Full Text] [Related]
14. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response.
Villegas A; Arrizabalaga B; Fernández-Lago C; Castro M; Mayans JR; González-Porras JR; Duarte RF; Remacha AF; Luño E; Gasquet JA
Curr Med Res Opin; 2011 May; 27(5):951-60. PubMed ID: 21381892
[TBL] [Abstract][Full Text] [Related]
15. Case history. 2: The use of epoetin alfa before high-dose chemotherapy.
Mertelsmann R
Ann Oncol; 1997; 8 Suppl 3():S13. PubMed ID: 9341961
[No Abstract] [Full Text] [Related]
16. [Long-acting erythropoetin efficacy in the treatment of nephrogenic anemia in patients with chronic kidney disease during predialysis stage].
Milovanov IuS; Milovanova LIu
Ter Arkh; 2012; 84(6):48-52. PubMed ID: 22997919
[TBL] [Abstract][Full Text] [Related]
17. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
18. Treatment options for myelodysplastic syndromes.
Stone R
Cancer Control; 2004; 11(6 Suppl):7-10. PubMed ID: 15625531
[No Abstract] [Full Text] [Related]
19. Change in darbepoetin alfa administration schedule affects erythropoiesis-stimulating agent resistance in patients with chronic kidney disease receiving hemodialysis.
Molina M; Navarro MJ; de Gracia C; Alvarez G; de Alarcon R; Garcia MA
Ren Fail; 2008; 30(8):778-83. PubMed ID: 18791951
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic growth factors in myelodysplastic syndromes.
Steensma DP
Semin Oncol; 2011 Oct; 38(5):635-47. PubMed ID: 21943670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
